Our Science

Attovia™ is innovating breakthrough medicines for disease areas with high unmet need, including dermatology, gastroenterology/IBD, and other immune-mediated diseases.

Using our ATTOBODY™ platform, we design novel complex biologics that aim to breakthrough the efficacy ceiling.

Pipeline & Technology

Attovia is innovating breakthrough medicines for disease areas with high unmet need, including dermatology, gastroenterology/IBD, and other immune-mediated diseases.

Using our proprietary ATTOBODY™ platform, we design novel multispecifics that inhibit two, three, or even four disease-driving pathways—within a single molecule.

Dermatology

PROGRAM INDICATION DISCOVERY IND ENABLING PHASE 1
  • ATTO-1310
    IL-31
 Chronic Puritis, High-itch AD
CPUO, CholeP, CKD-aP1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque in dignissim dolor. Sed a ornare augue. Fusce tincidunt ut tellus et fermentum.
  • ATTO-2306
    IL-31 X IL-13
 Inflammatory Skin Disease
AD, CSU, PN

1Planned future indications

Dermatology

Program Indication
  • ATTO-1310
    IL-31
 Chronic Puritis, High-itch AD
CPUO, CholeP, CKD-aP1

PHASE 1
  • ATTO-2306
    IL-31 x IL-13
 Inflammatory Skin Disease
AD, CSU, PN

 IND ENABLING

1Planned future indications

Gastroenterology

PROGRAM INDICATION DISCOVERY IND ENABLING PHASE 1
  • ATTO-1091
    TL1A x IL-23p19 x Integrin α4β7
 Inflammatory Bowel Disease
UC, CD

Gastroenterology

PROGRAM INDICATION
  • ATTO-1091
    TL1A x IL-23p19 x Integrin α4β7
 Inflammatory Bowel Disease
UC, CD

IND ENABLING

Immune-mediated Disease

PROGRAM INDICATION DISCOVERY IND ENABLING PHASE 1
  • ATTO-006
    TRM Survival Blocker
 Inflammatory Disease
Rheumatology, IBD

  • ATTO-007
    Immune Cell Survival Blocker
 Inflammatory Disease

  • ATTO-008
    Multi-alarmin Blocker
 Respiratory Disease
Asthma, COPD

Immune-mediated Disease

PROGRAM INDICATION
  • ATTO-006
    TRM Survival Blocker
 Inflammatory Disease
Rheumatology, IBD

DISCOVERY
  • ATTO-007
    Immune Cell Survival Blocker
 Inflammatory Disease

DISCOVERY
  • ATTO-008
    Multi-alarmin Blocker
 Respiratory Disease
Asthma, COPD

DISCOVERY

Learn more about our clinical program:

Phase 1 trial of ATTO-1310 (anti-IL-31) in Chronic Pruritus and High-itch Atopic Dermatitis

Status: Active, not recruiting

This study will first evaluate the safety and tolerability of ATTO-1310 in healthy adults after receiving single and multiple doses. The study will then evaluate the effect of a single dose of ATTO-1310 in adult patients with severe itching and either atopic dermatitis or chronic pruritus. All participants will be followed in the study for approximately 16 weeks after the last dose.

LEARN MORE ON CLINICALTRIALS.GOV

Unleashing the power of ATTOBODY platform to develop new breakthrough medicines

ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to high potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of precision-designed complex biologics. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at rapid speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice.

Interested in partnering?

Interested in partnering?